NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial
MWN-AI** Summary
NeuroRPM, a digital health firm specializing in Parkinson's disease management, has partnered with Annovis Bio to utilize its FDA-cleared wearable platform for monitoring digital biomarkers in the ANVS-25002 open-label clinical trial. This groundbreaking study aims to recruit around 500 participants with Parkinson's disease from various clinical locations. By leveraging the Apple Watch, NeuroRPM's platform is designed to collect and analyze movement data passively, enabling continuous tracking of core Parkinson's motor symptoms such as bradykinesia, tremor, and dyskinesia.
Traditional periodic assessments within clinical settings often fail to capture the daily fluctuations in Parkinson’s symptoms, which can vary significantly among patients. The NeuroRPM platform bridges this gap by providing a continuous measurement capability, allowing researchers to gain deeper insights into symptom behavior outside of clinical visits. Atila Omer, CEO of NeuroRPM, emphasized that the integration of real-world data allows for a more nuanced understanding of how therapies influence individual patients' daily lives.
This partnership is particularly significant given the accelerating role of AI in medical device applications. Maria Maccecchini, President and CEO of Annovis, noted this commitment to improving patient outcomes through evidence-based measurements in the context of ongoing clinical trials.
Following the trial, participants will have the option to continue utilizing the NeuroRPM platform for ongoing monitoring. This initiative not only aims to enhance the understanding of disease progression during the trial but also offers a potential long-term solution for patients living with Parkinson's disease. The collaboration underscores a shared commitment to advancing therapeutic options and improving quality of life for those affected by neurodegenerative diseases. For more information, visit NeuroRPM.com and AnnovisBio.com.
MWN-AI** Analysis
Investors should closely monitor the collaboration between NeuroRPM and Annovis Bio, particularly in the context of Alzheimer's and Parkinson's disease research. NeuroRPM, with its FDA-cleared AI-enabled wearable platform, aims to enhance traditional clinical trial methodologies by providing continuous and objective monitoring of Parkinson’s motor symptoms. This innovative approach leverages widely-used technology, the Apple Watch, to passively collect real-world data, a critical advancement given the variability of Parkinson’s symptoms throughout the day.
The ongoing ANVS-25002 clinical trial, which plans to enroll around 500 participants, represents a significant opportunity for both companies. As NeuroRPM's platform delivers granularity to symptom tracking, it can equip researchers and physicians with vital insights that are often lost in conventional in-clinic assessments. This could lead to a deeper understanding of how treatments work in real-life settings, thereby enhancing the efficacy of Annovis Bio’s lead drug candidate, buntanetap.
Annovis’ focus on neurodegenerative diseases makes it a compelling player in an under-targeted area of pharmaceutical development. Given that traditional therapies often provide limited insights into treatment effectiveness, the integration of NeuroRPM’s technology could position Annovis as a frontrunner in innovating treatment pathways for patients significantly affected by Parkinson's disease.
Investors should consider the long-term value proposition this partnership presents, particularly as AI continues to reshape healthcare delivery. With growing awareness of mental health and neurodegenerative conditions, the market for effective therapies is expanding. The convergence of advanced technology with biotech could yield significant returns, making NeuroRPM and Annovis Bio worthy of attention in an evolving marketplace. As developments unfold, maintaining vigilance on trial results and regulatory outcomes will be crucial for informed decision-making.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
WASHINGTON, D.C., March 19, 2026 (GLOBE NEWSWIRE) -- NeuroRPM, a digital health company focused on Parkinson’s disease monitoring, today announced that its FDA-cleared wearable platform will be used for digital biomarker monitoring in Annovis Bio’s ANVS-25002 open-label Parkinson’s disease clinical trial. NeuroRPM’s platform uses the Apple Watch to passively collect and analyze movement data during daily activities, providing continuous measurement of key Parkinson’s motor symptoms.
The ANVS-25002 study is expected to enroll approximately 500 participants with Parkinson’s disease across multiple clinical sites. Eligible participants may choose to take part in the NeuroRPM digital monitoring program to complement scheduled study assessments with continuous real-world symptom monitoring.
Parkinson’s symptoms often fluctuate throughout the day and vary across patients, making treatment response difficult to fully characterize through periodic in-clinic assessments alone. NeuroRPM addresses this gap by continuously and objectively measuring cardinal Parkinson’s motor symptoms, including bradykinesia, tremor, and dyskinesia, in real-world settings.
“Parkinson’s is experienced in everyday life, so researchers need tools that show what happens between scheduled assessments,” said Atila Omer, CEO of NeuroRPM. “Using Apple Watch to gather continuous movement data during daily life, we can translate those patterns into meaningful insights for researchers evaluating how therapies perform and affect individual patients in the real world.”
NeuroRPM developed the first FDA-cleared AI-enabled medical device for continuous monitoring of Parkinson’s disease symptoms. The NeuroRPM platform uses advanced algorithms and AI-enabled analysis to detect and interpret nuanced symptom patterns from wearable sensor data, helping researchers evaluate treatment response with greater granularity over time.
“We are living in an era where AI has moved beyond useful to essential, and disease management stands among the most transformative opportunities for its application,” commented Maria Maccecchini, Ph.D., President and CEO of Annovis. “We are proud to partner with NeuroRPM to bring into our study the AI-powered digital biomarker for monitoring Parkinson’s symptoms, adding an important layer of evidence-based measurement of disease progression throughout the trial.”
“Efforts like this are important because people living with Parkinson’s disease need better therapies and better ways to understand how those therapies work in daily life,” Omer added. “Annovis is advancing an innovative therapeutic program that could make a meaningful difference for people with Parkinson’s disease, and NeuroRPM is proud to contribute objective, AI-enabled monitoring to that work.”
A distinctive aspect of NeuroRPM’s research platform is its ability to place trial-based symptom patterns in the broader context of real-world Parkinson’s monitoring data generated in clinical care settings, giving researchers added perspective when interpreting symptom changes during the trial.
Following the study, participants may continue using NeuroRPM for ongoing clinical monitoring by prescription.
About Annovis Bio
Headquartered in Malvern, PA, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases including Alzheimer's disease and Parkinson's disease. The company's lead drug candidate, buntanetap, is an investigational once-daily oral therapy that inhibits translation of multiple neurotoxic proteins. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients.
For information about Annovis Bio’s ANVS-25002 study and Parkinson’s disease research program, visit the Patient Portal (https://www.annovisbio.com/parkinsons-disease).
About NeuroRPM Inc.
NeuroRPM is a digital health company focused on advancing objective measurement and management of Parkinson’s disease through AI-enabled wearable monitoring and data analytics. Its FDA-cleared platform uses wearable sensor data, advanced algorithms, and analytics to measure Parkinson’s motor symptoms in clinical care and research. For more information, visit NeuroRPM.com and follow us on LinkedIn and Instagram.
Contact:
Charlotte Yerkovich, Director of Clinical Adoption
301-437-8698
charlotte.y@neurorpm.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c0f01c70-1896-4eb2-ae43-a57c56e437d5
FAQ**
How will the collaboration between NeuroRPM and Annovis Bio Inc. ANVS enhance the understanding of Parkinson's disease symptoms during the ANVS-25002 clinical trial?
What specific AI-enabled features of NeuroRPM's platform will be utilized in the Annovis Bio Inc. ANVS-25002 study to monitor Parkinson’s motor symptoms?
How does the wearable technology from NeuroRPM improve the quality of data collected in the Annovis Bio Inc. ANVS-25002 clinical trial compared to traditional assessment methods?
What potential implications could the findings from the ANVS-25002 study have for the future treatment of Parkinson's disease through collaborations like that of NeuroRPM and Annovis Bio Inc. ANVS?
**MWN-AI FAQ is based on asking OpenAI questions about Annovis Bio Inc. (NYSE: ANVS).
NASDAQ: ANVS
ANVS Trading
-6.36% G/L:
$2.06 Last:
89,120 Volume:
$2.06 Open:
